ZUG, Switzerland, May 28, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (Nasdaq:EARS) today provided an update on the Company’s business and announced financial results for the first quarter ended March 31, 2015.
“Auris Medical continued to make strong progress in the first months of 2015,” commented Thomas Meyer, the Company’s founder, Chairman and CEO. “Enrollment into our AM-101 Phase 3 trials in the treatment of acute inner ear tinnitus advanced well, and through our recent equity raise we laid the groundwork for moving forward with an expanded AM-111 late-stage clinical development program. The treatment of acute inner ear hearing loss with AM-111 addresses an important unmet medical need and represents a substantial commercial opportunity for Auris Medical.”
Help employers find you! Check out all the jobs and post your resume.
